Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Advanced Solid MalignancyAdvanced Solid Tumor

Interventions

DRUG

AZD5363

Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.

Trial Locations (1)

Research Site, Chūōku